VRAX VRAX
Company Profile ↓Company Overview
VRAX (VRAX) is a publicly traded company listed on with a market capitalization of $1.52M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 13.2% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.05.
Recent Developments
- Mar 2026 Revenue of $12.42K (+96.2% YoY); net profit $-5.02M.
- Trailing 12 Months Year-on-year growth — revenue +96.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 13.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 13.21% |
| 1 Year: | 96.22% |
Stock Price Performance
| 1 Year: | -86.00% |
| 6 Months: | -51.16% |
| 3 Months: | -50.70% |
| 1 Month: | -5.23% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.12 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 13.2% over 5 years.
CONS
- Trading 86.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 8.56K | 156.42K | 6.33K | 12.42K |
| Cost of Revenue | - | 9.93K | 105.83K | 59.40K | 4.73K |
| Gross Profit | - | -1.36K | 50.59K | -53.07K | 7.69K |
| Operating Expenses | - | 5.73M | 6.19M | 6.02M | 6.41M |
| Operating Income | - | -5.73M | -6.14M | -6.08M | -6.40M |
| EBITDA | - | -5.44M | -6.61M | -5.80M | -5.43M |
| Interest Expense | - | 15.47K | 26.88K | 58.18K | 61.77K |
| Pretax Income | - | -5.46M | -6.74M | -6.20M | -5.93M |
| Tax Provision | - | 0 | 0 | -136.66K | -900.24K |
| Net Income | - | -5.46M | -6.73M | -6.06M | -5.02M |
| Diluted EPS | - | -128.25 | -83.90 | -40.62 | -12.64 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 9.81M | 5.48M | 6.43M | 8.32M |
| Current Assets | - | 9.63M | 4.38M | 4.89M | 6.83M |
| Cash & Equivalents | - | 9.35M | 3.59M | 4.23M | 6.44M |
| Inventory | - | 0 | 60.38K | 94.67K | 0 |
| Receivables | 0 | - | - | - | - |
| Total Liabilities | - | 908.40K | 345.19K | 964.75K | 989.83K |
| Current Liabilities | - | 908.40K | 168.85K | 673.21K | 685.02K |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 146.25K | 224.30K | 377.00K | 414.39K |
| Total Equity | - | 9.13M | 5.37M | 5.70M | 7.58M |
| Shares Outstanding | - | 62.19K | 102.96K | 173.68K | 579.22K |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -4.18M | -6.40M | -4.56M | -4.62M |
| Investing Cash Flow | - | -178.40K | -1.16M | -603.89K | -255.83K |
| Financing Cash Flow | - | 13.69M | 1.80M | 5.81M | 7.09M |
| Capital Expenditure | - | -178.40K | -1.16M | -603.89K | -255.83K |
| Free Cash Flow | - | -4.36M | -7.56M | -5.17M | -4.88M |
| Net Change in Cash | - | 9.33M | -5.76M | 639.70K | 2.21M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | -15.9% | 32.3% | -838.2% | 61.9% |
| Operating Margin % | - | -66,963.7% | -3,922.4% | -95,984.9% | -51,515.2% |
| Net Margin % | - | -63,748.3% | -4,304.8% | -95,739.2% | -40,439.1% |
| ROE % | - | -59.8% | -125.5% | -106.4% | -66.3% |
| ROCE % | - | -64.4% | -115.4% | -105.6% | -83.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VRAX
Virax Biolabs (VRAX) expands at-the-market stock sale plan - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNTzA5cE55cVM5cmZxOUVRY3RURFpQbW92dmp6YWFxaVBlS0pNeHV1eFY2N0dlVnBTM0w4YXIweHJ6SEE0VlF6YmV0akpFVnROdWU2TWRYNEJQTnlveUU4SUZNV2hjb0RaWkx3YVpKQWpmVzRud3hxLURRRFctamY4ZDBFbExzNGY1aUVCaE…
VRAX Stock Sees Volatile Moves As Traders Track Support - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxOZG1jQUd5MmFlOUpJRjRlcnhxZy16aThaQ2NxN3dHWVJpaVhqMnE3b2hscjJEN0lna1dQVDJfdUlVYlA4WkQ1ZEtqdGx3eVNPNnVFVVlNRXlaOTdsVTlKQ3FwVkt6YWpPeGdvSU44UHRqYTYzeVJnR3pJUWRwNms5VFc0UGFLMnJ6OVE?oc…
Why Did Virax Biolabs Stock Triple In One Session? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQTDBhU1paNWRQWmxjSEZtbk1QaERiQWM3c3lXQ3Y3LUFSdkJFa3BobmUydEFRNzdRZTR6ZGp2VndHaTJUZG1CMXpQMmw5aUtudmZiTUttVTVOSTg0ekxpMno2NXBuWFFNN3VScm0yMTZiZ09BeWs2OWpGaXhrblFNZEpmaEtCT2puNjBVaj…
Virax Biolabs (VRAX) surges 177% as low-float momentum meets extreme short interest | VRAX Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQOGhraHI4TERmckhuakR2UHRaVEswV053bUhYNmlvaFRtY19FUWpabjk2VGh2SmNoYnVlOWl3bVBfWTUyUEZwckg3Z2IwbkRVcFFWdFhER19oM2FMUUZoVUQtMGh1VC1GTUxIaHc4VG1ydFRFSEdweGZBMkd0bXM3NjhrRTk4SldDZUxXUn…
VRAX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE8xU3BPSDBwX2tWTTQ3LVZEY3JlTFF6MS10YmRUdzBGRkY1VjZLNU9GbmJpVEtXam9hRUFKLTRIOEhyaWJzWnc?oc=5" target="_blank">VRAX</a> <font color="#6f6f6f">Finviz</font>…
Virax Biolabs Group Ltd SEC Filing (Sep 4, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOWjBTWEhNMnpuU0RlLWRJbUdwcGdjS21QdFhDYUN5UGdhTUNaa25UempiMF90NzAyQ3VPaTNtZWt4OGNiTzl2UXFMbmstR216SEs3TTZLaVh1N0dkeFVzdjhGR3JHdUFHejZSWTZoME9xS1NTRjJNOUZmUU1pMGV3RnlHakZlYkwtZGprU2…
VRAX — Frequently Asked Questions
What is the current share price of VRAX?
As of 2026-09-19 21:16 PDT, VRAX trades at $2.62 on NASDAQ/NYSE. Its 52-week range is $2.54 to $19.58.
What is the market capitalisation of VRAX?
VRAX has a market capitalisation of $1.52M on NASDAQ/NYSE.
What is the P/E ratio of VRAX?
VRAX trades at a trailing price-to-earnings (P/E) ratio of -0.21. Its price-to-book (P/B) ratio is 0.20.
What is the return on equity (ROE) of VRAX?
VRAX has a return on equity (ROE) of -66.30%. Its return on capital employed (ROCE) is -83.77%.
Is VRAX a good stock to buy?
This page provides a data-driven analysis of VRAX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.